These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 26516226)

  • 1. Immunosuppressive mechanisms in glioblastoma.
    Nduom EK; Weller M; Heimberger AB
    Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii9-vii14. PubMed ID: 26516226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The network of immunosuppressive pathways in glioblastoma.
    Mangani D; Weller M; Roth P
    Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.
    Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA
    World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma-derived mechanisms of systemic immunosuppression.
    Waziri A
    Neurosurg Clin N Am; 2010 Jan; 21(1):31-42. PubMed ID: 19944964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.
    Pellegatta S; Cuppini L; Finocchiaro G
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1759-74. PubMed ID: 22050025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
    Daubon T; Hemadou A; Romero Garmendia I; Saleh M
    Front Immunol; 2020; 11():585616. PubMed ID: 33154756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
    Sinnadurai M; McDonald KL
    J Neurooncol; 2017 May; 132(3):359-372. PubMed ID: 28293764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing the immune system in glioblastoma.
    Brown NF; Carter TJ; Ottaviani D; Mulholland P
    Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer immunotherapy. Importance of overcoming immune suppression].
    Malvicini M; Puchulo G; Matar P; Mazzolini G
    Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
    Lucca LE; Hafler DA
    Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dynamics of Interactions Among Immune and Glioblastoma Cells.
    Eder K; Kalman B
    Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
    Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
    World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.
    Amin T; Hossain A; Jerin N; Mahmud I; Rahman MA; Rafiqul Islam SM; Islam SMBU
    Cancer Control; 2024; 31():10732748241290067. PubMed ID: 39353594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in human glioblastoma.
    Szabo AT; Carpentier AF
    Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological challenges for peptide-based immunotherapy in glioblastoma.
    Mohme M; Neidert MC; Regli L; Weller M; Martin R
    Cancer Treat Rev; 2014 Mar; 40(2):248-58. PubMed ID: 24064197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma-activated pericytes support tumor growth via immunosuppression.
    Sena IFG; Paiva AE; Prazeres PHDM; Azevedo PO; Lousado L; Bhutia SK; Salmina AB; Mintz A; Birbrair A
    Cancer Med; 2018 Apr; 7(4):1232-1239. PubMed ID: 29479841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research.
    Khansur E; Shah AH; Lacy K; Komotar RJ
    Cancer Invest; 2019; 37(1):1-7. PubMed ID: 30632816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological Evasion in Glioblastoma.
    Magaña-Maldonado R; Chávez-Cortez EG; Olascoaga-Arellano NK; López-Mejía M; Maldonado-Leal FM; Sotelo J; Pineda B
    Biomed Res Int; 2016; 2016():7487313. PubMed ID: 27294132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.